AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics


AcelRx Pharmaceuticals, Inc. (ACRX): $1.02

0.01 (+0.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACRX POWR Grades


  • ACRX scores best on the Growth dimension, with a Growth rank ahead of 60% of US stocks.
  • The strongest trend for ACRX is in Momentum, which has been heading down over the past 51 weeks.
  • ACRX ranks lowest in Quality; there it ranks in the 2nd percentile.

ACRX Stock Summary

  • Acelrx Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.69% of US listed stocks.
  • ACRX's price/sales ratio is 39.34; that's higher than the P/S ratio of 94.06% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.69 for Acelrx Pharmaceuticals Inc; that's greater than it is for only 4.56% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Acelrx Pharmaceuticals Inc, a group of peers worth examining would be SIBN, APYX, CREX, BXRX, and ECOR.
  • Visit ACRX's SEC page to see the company's official filings. To visit the company's web site, go to www.acelrx.com.

ACRX Valuation Summary

  • ACRX's EV/EBIT ratio is -3.8; this is 112.97% lower than that of the median Healthcare stock.
  • Over the past 128 months, ACRX's price/sales ratio has gone NA NA.
  • ACRX's price/sales ratio has moved NA NA over the prior 128 months.

Below are key valuation metrics over time for ACRX.

Stock Date P/S P/B P/E EV/EBIT
ACRX 2021-08-31 43.6 -3.7 -3.6 -3.8
ACRX 2021-08-30 44.0 -3.7 -3.7 -3.9
ACRX 2021-08-27 43.2 -3.7 -3.6 -3.8
ACRX 2021-08-26 44.0 -3.7 -3.7 -3.9
ACRX 2021-08-25 42.5 -3.6 -3.5 -3.7
ACRX 2021-08-24 43.2 -3.7 -3.6 -3.8

ACRX Growth Metrics

  • Its 5 year price growth rate is now at -57.75%.
  • The 5 year revenue growth rate now stands at -87.49%.
  • Its year over year net income to common stockholders growth rate is now at 39.79%.
ACRX's revenue has moved up $650,000 over the prior 15 months.

The table below shows ACRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 3.06 -32.506 -36.655
2021-03-31 5.541 -33.849 -33.41
2020-12-31 5.416 -38.505 -40.379
2020-09-30 5.153 -46.333 -45.884
2020-06-30 4.393 -49.675 -49.685
2020-03-31 2.41 -52.304 -55.491

ACRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACRX has a Quality Grade of F, ranking ahead of 2.03% of graded US stocks.
  • ACRX's asset turnover comes in at 0.041 -- ranking 336th of 681 Pharmaceutical Products stocks.
  • JNJ, ORGS, and ABBV are the stocks whose asset turnover ratios are most correlated with ACRX.

The table below shows ACRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.041 -0.709 -0.606
2021-03-31 0.077 -0.004 -0.552
2020-12-31 0.078 -0.114 -0.640
2020-09-30 0.068 -0.232 -0.616
2020-06-30 0.052 -0.513 -0.580
2020-03-31 0.025 -1.941 -0.632

ACRX Price Target

For more insight on analysts targets of ACRX, see our ACRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.00 Average Broker Recommendation 1.33 (Strong Buy)

ACRX Stock Price Chart Interactive Chart >

Price chart for ACRX

ACRX Price/Volume Stats

Current price $1.02 52-week high $2.94
Prev. close $1.01 52-week low $0.75
Day low $1.01 Volume 679,200
Day high $1.04 Avg. volume 3,085,532
50-day MA $1.06 Dividend yield N/A
200-day MA $1.46 Market Cap 121.56M

AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.


ACRX Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRX Latest Social Stream


Loading social stream, please wait...

View Full ACRX Social Stream

Latest ACRX News From Around the Web

Below are the latest news stories about Acelrx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACRX as an investment opportunity.

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

Appointment of New Director with Significant Experience in Drug Development, Licensing and CommercializationSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Dr. De

Yahoo | October 4, 2021

AcelRx Pharmaceuticals to Participate in Two September Investor Conferences

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference taking place September 13-15, 2021, and at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27

Yahoo | September 10, 2021

Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P. (NASDAQ:ACRX)Lifshitz Law Firm, P.

Yahoo | August 30, 2021

Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27th at the Miami Beach Convention Center in Miami Beach, Florida.

Yahoo | August 30, 2021

Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.

Yahoo | August 26, 2021

Read More 'ACRX' Stories Here

ACRX Price Returns

1-mo 0.00%
3-mo -17.07%
6-mo -18.40%
1-year -46.03%
3-year -71.90%
5-year -67.10%
YTD -17.74%
2020 -41.23%
2019 -8.66%
2018 14.07%
2017 -22.12%
2016 -32.47%

Continue Researching ACRX

Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:

Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9576 seconds.